Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17851417 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | June 2022 | January 2023 | Allow | 60 | 0 | 0 | Yes | No |
| 16970083 | BLOCKING TYPE PD-L1 SINGLE-DOMAIN CAMEL ANTIBODY AND APPLICATION THEREOF | January 2021 | December 2023 | Allow | 41 | 0 | 1 | Yes | No |
| 17257294 | Novel CD47 Antibodies and Methods of Using Same | December 2020 | December 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17137875 | METHODS OF TREATING SPINAL CORD INJURY USING A CHONDROITIN SULFATE PROTEOGLYCAN (CSPG) REDUCTION PEPTIDE (CRP) COMPRISING A CELL MEMBRANE PENETRATING DOMAIN, A CSPG BINDING DOMAIN, AND A LYSOSOME TARGETING DOMAIN | December 2020 | December 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 17136189 | TAU-BINDING ANTIBODIES | December 2020 | April 2023 | Allow | 27 | 1 | 0 | No | No |
| 17136440 | TAU-BINDING ANTIBODIES | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17255796 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | December 2020 | February 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17133213 | HOME PREGNANCY PROGRESSION TESTING SYSTEM AND METHOD | December 2020 | May 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17255692 | ANTIBODY BINDING TO CHONDROITIN SULFATE PROTEOGLYCAN 5 | December 2020 | January 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17255784 | ANTIBODY BINDING TO CELL ADHESION MOLECULE 3 | December 2020 | September 2023 | Allow | 32 | 1 | 0 | No | No |
| 17255776 | ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHIES AND NEUROINFLAMMATION | December 2020 | July 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17130477 | BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE | December 2020 | July 2023 | Allow | 31 | 2 | 0 | No | No |
| 17128110 | B-CELL EPITOPE OF TRICHINELLA SPIRALIS CYSTEINE PROTEASE INHIBITOR, HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND USES THEREOF | December 2020 | December 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17127629 | MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS | December 2020 | October 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17127934 | Composition and Method for Improving Sensorineural Hearing | December 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17127913 | ANTI-RYK ANTIBODIES AND METHODS OF USING THE SAME | December 2020 | July 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17127719 | ANTI-TRANSTHYRETIN ANTIBODIES | December 2020 | September 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 17127324 | LINGO-1 ANTAGONISTS AND USES FOR TREATMENT OF DEMYELINATING DISORDERS | December 2020 | September 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17126677 | ANTIBODY FOR SKEWING SEX RATIO AND METHODS OF USE THEREOF | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17125734 | ILT3-BINDING AGENTS AND METHODS OF USE THEREOF | December 2020 | April 2023 | Allow | 28 | 1 | 1 | No | No |
| 17125108 | DOSING REGIMENS FOR TARGETED TGF-B INHIBITION FOR USE IN TREATING BILIARY TRACT CANCER | December 2020 | January 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17253391 | FUSION PROTEINS COMPRISING PROGRANULIN | December 2020 | May 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17253584 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | December 2020 | June 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17125172 | METHODS FOR IMPROVING DRUG EFFICACY | December 2020 | January 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17043054 | SINGLE-DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF | December 2020 | January 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17122325 | HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME | December 2020 | April 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17121553 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN G | December 2020 | July 2023 | Allow | 31 | 1 | 0 | No | No |
| 17251411 | ANTIBODY CAPABLE OF BLOCKING CD47-SIRPA INTERACTION AND APPLICATION THEREOF | December 2020 | July 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17119410 | ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR | December 2020 | June 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17119035 | METHODS OF TREATING ACID SPHINGOMYELINASE DEFICIENCY | December 2020 | January 2024 | Allow | 37 | 2 | 0 | No | No |
| 17119075 | APOAEQUORIN AND VITAMIN D-CONTAINING COMPOSITIONS AND METHODS OF USING SAME | December 2020 | April 2024 | Allow | 40 | 4 | 0 | Yes | No |
| 17118395 | ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM | December 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17118353 | METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17116104 | PREPARATION OF FLAGELLIN VACCINE ADJUVANT-BASED VACCINE TO INDUCE PRODUCTION OF ANTIBODY RECOGNIZING CONFORMATION OF ANTIGENS, AND APPLICATION THEREOF | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17114984 | Autoantibodies to Septin-7 and Diagnosis of Neurological Disease | December 2020 | September 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 17113559 | p53 Peptides as Markers in the Diagnosis and Prognosis of Alzheimer's Disease | December 2020 | January 2023 | Allow | 25 | 4 | 0 | Yes | No |
| 17113711 | Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy | December 2020 | April 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17111159 | ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF | December 2020 | September 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 17110512 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | December 2020 | May 2023 | Abandon | 29 | 1 | 0 | No | No |
| 15734885 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | December 2020 | September 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17110969 | ANTI-TAU ANTIBODIES AND METHODS OF USE | December 2020 | September 2022 | Allow | 21 | 0 | 0 | No | No |
| 17109604 | ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN | December 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 15733838 | COMPOSITIONS AND USES THEREOF FOR TREATING DISEASE OR CONDITION | November 2020 | January 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17059268 | ANTI-THYROID HORMONE (T4) RECOMBINANT ANTIBODY OR ANTIGEN BINDING FRAGMENT | November 2020 | October 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 17058728 | ANTI-OX40 ANTAGONISTIC ANTIBODIES AND DOSAGE FOR THE TREATMENT OF OX40-MEDIATED DISORDERS | November 2020 | October 2023 | Abandon | 35 | 1 | 1 | No | No |
| 17058961 | POLYPEPTIDE COMPRISING AGGRECAN BINDING DOMAIN AND CARRYING MOIETY | November 2020 | March 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17104886 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING EARLY BIOMARKERS | November 2020 | May 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17104344 | Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators | November 2020 | December 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17104848 | METHODS OF BINDING AMYLOID BETA PROTEIN HAVING PYROGLUTAMATE AT THE THIRD AMINO ACID RESIDUE (3pE ABETA) IN VIVO USING ANTI-3pE ABETA ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF | November 2020 | January 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17058446 | METHODS AND COMPOSITIONS FOR PERTUSSIS DIAGNOSIS | November 2020 | October 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 17057429 | REAGENTS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASE | November 2020 | December 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17057607 | A NOVEL ANTI-CD3/ANTI-CD20 BISPECIFIC ANTIBODY | November 2020 | June 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17056816 | BIOPHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODY VARIANTS | November 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 16951012 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | November 2020 | August 2024 | Abandon | 45 | 3 | 1 | Yes | No |
| 17056035 | BIOMARKER METHODS FOR TREATMENT OF ATOPIC DISEASE BY IMMUNOTHERAPY | November 2020 | March 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17099247 | COMPOSITIONS AND METHODS FOR REGULATING SAS1R | November 2020 | July 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17099668 | METHODS FOR AIDING IN THE DETERMINATION OF WHETHER TO PERFORM IMAGING ON A HUMAN SUBJECT WHO HAS SUSTAINED OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD USING EARLY BIOMARKERS | November 2020 | May 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17098790 | METHOD OF INHIBITING THE GROWTH OF LIVER CANCER CELLS, AND METHOD OF TREATING LIVER CANCER | November 2020 | March 2024 | Abandon | 40 | 2 | 0 | Yes | No |
| 17098970 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE | November 2020 | March 2023 | Allow | 28 | 1 | 0 | No | No |
| 17097457 | AGENT, USES AND METHODS FOR TREATMENT | November 2020 | August 2022 | Allow | 21 | 0 | 0 | No | No |
| 17098199 | ANTIBODIES BINDING TO Alpha7Beta1 INTEGRIN ANTIBODIES AND COMPOSITIONS THEREOF | November 2020 | June 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17097592 | COMPOSITION CONTAINING PORIA COCOS PEEL EXTRACT FOR TREATING NEURODEGENERATIVE DISORDERS | November 2020 | January 2023 | Abandon | 26 | 1 | 0 | Yes | No |
| 17096901 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | November 2020 | November 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17054609 | BIORESPONSIVE HYDROGEL MATRIXES AND METHODS OF USE | November 2020 | October 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17095695 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY USING EARLY BIOMARKERS ON AT LEAST TWO SAMPLES FROM THE SAME HUMAN SUBJECT | November 2020 | May 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17094950 | METHODS OF REDUCING NEUROINFLAMMATION OR TOXICITY INDUCED BY AMYLOID BETA (ABETA) USING GLUCOCORTICOID INDUCED LEUCINE ZIPPER (GILZ) ANALOG PEPTIDES | November 2020 | June 2022 | Allow | 19 | 1 | 1 | Yes | No |
| 17054469 | ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF | November 2020 | December 2023 | Allow | 37 | 2 | 0 | No | No |
| 17093251 | METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER | November 2020 | October 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17093541 | ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOF | November 2020 | August 2021 | Allow | 10 | 2 | 0 | Yes | No |
| 17093527 | ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOF | November 2020 | August 2021 | Allow | 9 | 2 | 0 | No | No |
| 17053346 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | November 2020 | May 2024 | Allow | 43 | 1 | 0 | No | No |
| 17090359 | Immunological Targeting of Pathological Tau Proteins | November 2020 | June 2023 | Allow | 31 | 1 | 1 | No | No |
| 17052817 | COMBINED THERAPY WITH ICOS BINDING PROTEINS AND ARGININEMETHYLTRANSFERASE INHIBITORS | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17089599 | ANTIBODIES RECOGNIZING TAU | November 2020 | December 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17089416 | ANTIBODIES RECOGNIZING TAU | November 2020 | October 2022 | Allow | 23 | 1 | 0 | No | No |
| 17052606 | COMBINATION OF A TYPE II PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR AND AN ICOS BINDING PROTEIN TO TREAT CANCER | November 2020 | January 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17088307 | AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY | November 2020 | August 2022 | Allow | 21 | 1 | 0 | No | No |
| 17086158 | Methods For Detecting Phosphorylated Alpha-Synuclein | October 2020 | June 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17084893 | METHODS FOR TREATING HEART DISEASE IN A SUBJECT WITH FRIEDREICH'S ATAXIA BY AN AROMATIC-CATIONIC PEPTIDE | October 2020 | January 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17084568 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I AND EARLY BIOMARKERS | October 2020 | November 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 17082687 | ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY | October 2020 | August 2023 | Allow | 34 | 2 | 0 | No | No |
| 17051165 | SKIN OINTMENT FOR TREATING LABIA MINORA SKIN | October 2020 | September 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17081013 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | October 2020 | August 2023 | Allow | 33 | 2 | 0 | No | No |
| 17050947 | ANTIBODY DIRECTED AGAINST A TAU-DERIVED NEUROTOXIC PEPTIDE AND USES THEREOF | October 2020 | September 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17050579 | A Method For Preparing PHFS-Like Tau Aggregates | October 2020 | October 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 17080180 | METHODS OF TREATING PRADER-WILLI SYNDROME | October 2020 | December 2023 | Allow | 38 | 1 | 1 | No | No |
| 17078678 | IN VITRO DETECTION OF PRIONS | October 2020 | January 2023 | Allow | 27 | 4 | 1 | Yes | No |
| 17050064 | OPTIMIZED ANTI-TL1A ANTIBODIES | October 2020 | September 2024 | Abandon | 47 | 1 | 0 | No | No |
| 17050056 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN | October 2020 | December 2022 | Allow | 25 | 2 | 0 | No | No |
| 17050072 | SERUM ALBUMIN BINDING ANTIBODIES FOR TUNEABLE HALF-LIFE EXTENSION OF BIOLOGICS | October 2020 | April 2022 | Allow | 18 | 1 | 0 | Yes | No |
| 17077041 | ENGINEERED THERAPEUTIC TO ENHANCE CYTOTOXIC ACTIVITY AND PHAGOCYTOSIS IN TUMOR ASSOCIATED MACROPHAGES | October 2020 | June 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17049800 | Potent Zika Virus-Specific and Cross-Neutralizing Monoclonal Antibodies to Zika and Dengue Viruses Following Zikv Infection or Vaccination | October 2020 | September 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 17049435 | COMBINATION OF METFORMIN AND CYCLOPHOSPHAMIDE AS AN ADJUVANT IN CANCER IMMUNOTHERAPY | October 2020 | January 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17076772 | TREATING REFRACTORY MIGRAINE | October 2020 | March 2021 | Allow | 5 | 1 | 0 | No | No |
| 17076759 | TREATING REFRACTORY MIGRAINE | October 2020 | March 2021 | Allow | 5 | 1 | 0 | No | No |
| 17074471 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | October 2020 | June 2024 | Abandon | 44 | 3 | 1 | No | No |
| 17072549 | MULTISPECIFIC ANTIBODIES AND USE THEREOF | October 2020 | August 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17072939 | MATERIALS AND METHODS FOR TREATING VITILIGO | October 2020 | April 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17072946 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEUROLOGICAL DISORDERS | October 2020 | April 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17073242 | IDENTIFICATION OF SPATIAL BIOMARKERS OF BRAIN DISORDERS AND METHODS OF USING THE SAME | October 2020 | June 2024 | Abandon | 44 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1649.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1649 is part of Group 1640 in Technology Center 1600. This art unit has examined 8,517 patent applications in our dataset, with an overall allowance rate of 42.1%. Applications typically reach final disposition in approximately 34 months.
Art Unit 1649's allowance rate of 42.1% places it in the 4% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1649 receive an average of 2.01 office actions before reaching final disposition (in the 59% percentile). The median prosecution time is 34 months (in the 31% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.